Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 18;12(2):218–226. doi: 10.1111/1759-7714.13748

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

(a) Swimmer plot for duration of disease stability or response to immune checkpoint inhibitors in patients with exon 20 mutation of EGFR or HER2. A total of 15 patients received immunotherapy including nine patients with EGFR Ex20ins and six with HER2 Ex20ins. Bar length indicates the duration of immunotherapy treatment for each patient, with the response observed before treatment failure indicated on the right. The origin corresponds to treatment start date, and the arrow indicates an ongoing response at the time of data censoring , PD‐L1 ≥1%; , PD‐L1 <1%. (b) Computed tomography scans of the thorax performed prior (baseline) and after anti‐PD‐1 treatment onset in four patients. The red arrow shows the lung lesion.

Inline graphic — (a) Swimmer plot for duration of disease stability or response to immune checkpoint inhibitors in patients with exon 20 mutation of EGFR or HER2. A total of 15 patients received immunotherapy including nine patients with EGFR Ex20ins and six with HER2 Ex20ins. Bar length indicates the duration of immunotherapy treatment for each patient, with the response observed before treatment failure indicated on the right. The origin corresponds to treatment start date, and the arrow indicates an ongoing response at the time of data censoring , PD‐L1 ≥1%; , PD‐L1 <1%. (b) Computed tomography scans of the thorax performed prior (baseline) and after anti‐PD‐1 treatment onset in four patients. The red arrow shows the lung lesion.